{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:59:33Z","timestamp":1790207973367,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejpb.2015.05.020","type":"journal-article","created":{"date-parts":[[2015,5,31]],"date-time":"2015-05-31T11:30:32Z","timestamp":1433071832000},"page":"398-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"PB","title":["Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles"],"prefix":"10.1016","volume":"95","author":[{"given":"Yoo Chun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F.","family":"Edelhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.05.020_b0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","article-title":"Ocular delivery of macromolecules","volume":"190","author":"Kim","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.05.020_b0010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2015.05.020_b0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/polym3010193","article-title":"Recent advances in ocular drug delivery systems","volume":"3","author":"Kuno","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.ejpb.2015.05.020_b0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0090-6980(92)90013-J","article-title":"Prostaglandin E2 binding site distribution and subtype classification in the rabbit iris-ciliary body","volume":"44","author":"Csukas","year":"1992","journal-title":"Prostaglandins"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpb.2015.05.020_b0025","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","article-title":"Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction","volume":"53","author":"Toris","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.020_b0030","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.05.020_b0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425247.4.4.371","article-title":"Novel approaches to retinal drug delivery","volume":"4","author":"Janoria","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.05.020_b0040","unstructured":"I. Merck & Co., Timoptic\u00ae 0.25% and 0.5% (Timolol Maleate Ophthalmic Solution) [Packing Insert], Merck & Co., Inc., Whitehouse Station, NJ 08889, USA, 2005."},{"key":"10.1016\/j.ejpb.2015.05.020_b0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.eye.6701515","article-title":"Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population","volume":"19","author":"Bhatt","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2015.05.020_b0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0008-4182(05)80119-X","article-title":"Complications of intravitreal injection of triamcinolone acetonide","volume":"40","author":"Ozkiris","year":"2005","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.020_b0055","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/112067210501500407","article-title":"Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide","volume":"15","author":"Jonas","year":"2005","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.020_b0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.020_b0065","first-page":"1533","article-title":"Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye","volume":"43","author":"Einmahl","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.020_b0070","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s10384-009-0725-0","article-title":"In vivo and in vitro study of suprachoroidal fibrin glue","volume":"53","author":"Hou","year":"2009","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.020_b0075","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1167\/iovs.06-0670","article-title":"Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging","volume":"48","author":"Kim","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.020_b0080","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.020_b0085","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1167\/iovs.05-1540","article-title":"A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis","volume":"47","author":"Gilger","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.020_b0090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.05.020_b0095","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.020_b0100","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/adhm.201300696","article-title":"Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye","volume":"3","author":"Kim","year":"2014","journal-title":"Adv. Health. Mater."},{"key":"10.1016\/j.ejpb.2015.05.020_b0105","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/sj.eye.6702029","article-title":"Suprachoroidal silicone oil: recognition and possible mechanisms","volume":"20","author":"Patel","year":"2006","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2015.05.020_b0110","series-title":"Drug Product Development for the Back of the Eye","first-page":"331","article-title":"Targeted drug delivery to the eye enabled by microneedles","author":"Patel","year":"2011"},{"key":"10.1016\/j.ejpb.2015.05.020_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10529-006-9219-z","article-title":"Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications","volume":"29","author":"Kogan","year":"2007","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ejpb.2015.05.020_b0120","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3928\/1542-8877-19940801-13","article-title":"Postoperative intraocular-pressure changes with use of different viscoelastics","volume":"25","author":"Dada","year":"1994","journal-title":"Ophthalmic Surg. Las."},{"key":"10.1016\/j.ejpb.2015.05.020_b0125","first-page":"49","article-title":"Use of viscoelastic solutions in ophthalmology \u2013 a review of physical-properties and long-term effects","volume":"2","author":"Silver","year":"1992","journal-title":"J. Long-Term Eff. Med."},{"key":"10.1016\/j.ejpb.2015.05.020_b0130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2165\/00003495-199447030-00009","article-title":"Hyaluronic-acid \u2013 a review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound-healing","volume":"47","author":"Goa","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2015.05.020_b0135","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jbm.a.30623","article-title":"Rheological and cohesive properties of hyaluronic acid","volume":"76A","author":"Falcone","year":"2006","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ejpb.2015.05.020_b0140","unstructured":"DisCoVisc (Ophthalmic Viscosurgical Device) Package Insert, in: I. Alcon Laboratories (Ed.), Alcon Laboratories Inc., 2006, 2011."},{"key":"10.1016\/j.ejpb.2015.05.020_b0145","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1039\/C1CS15203C","article-title":"Injectable and biodegradable hydrogels: gelation, biodegradation and biomedical applications","volume":"41","author":"Li","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejpb.2015.05.020_b0150","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.progpolymsci.2012.08.002","article-title":"Recent progress of in situ formed gels for biomedical applications","volume":"38","author":"Ko","year":"2013","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ejpb.2015.05.020_b0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.drudis.2013.01.013","article-title":"Injectable implants for the sustained release of protein and peptide drugs","volume":"18","author":"Agarwal","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2015.05.020_b0160","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","article-title":"In situ forming implants \u2013 an attractive formulation principle for parenteral depot formulations","volume":"161","author":"Kempe","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.05.020_b0165","series-title":"Handbook of Pharmaceutical Excipients","author":"Rowe","year":"2012"},{"key":"10.1016\/j.ejpb.2015.05.020_b0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000336045","article-title":"Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results","volume":"227","author":"Tetz","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ejpb.2015.05.020_b0175","unstructured":"V. Morales-Canton, R.R. Vera, M. Widmann, S.R. Patel, B. Yerxa, Suprachoroidal microinjection of bevacizumab is well tolerated in human patients, in: ARVO, Seattle, WA, 2014."},{"key":"10.1016\/j.ejpb.2015.05.020_b0180","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted delivery of anti-glaucoma drugs to the supraciliary space using microneedles","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.020_b0185","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-3-642-00477-3_16","article-title":"Medical devices for the treatment of eye diseases","author":"Yasukawa","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.05.020_b0190","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.05.020_b0195","unstructured":"A. Garcia, J. Tully, S. Das, T. Pegoraro, L. Trevino, B. Maynor, T. Navratil, B. Yerxa, Precisely engineered biodegradable drug delivery systems for the extended release of prostaglandin analogues in the anterior chamber, in: ARVO, Orlando, FL, 2014."},{"key":"10.1016\/j.ejpb.2015.05.020_b0200","series-title":"Vitreoretinal Surgical Techniques","author":"Peyman","year":"2001"},{"key":"10.1016\/j.ejpb.2015.05.020_b0205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/bjo.73.6.435","article-title":"Useful adjuncts for vitreoretinal surgery","volume":"73","author":"Gross","year":"1989","journal-title":"Br. J. Ophthalmol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115002520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115002520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T06:29:44Z","timestamp":1652164184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115002520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":41,"alternative-id":["S0939641115002520"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.05.020","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}